

2 September 2025

Haematology Treatment in Secondary Care

QUESTIONS:

NON-HODGKIN'S LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) AND ACUTE MYELOID LEUKAEMIA (AML)

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Acalabrutinib (Calquence)	
1.2 Ibrutinib (Imbruvica)	
1.3 Pirtobrutinib (Jaypirca)	
1.4 Venetoclax (Venclyxto)	
1.5 Zanubrutinib (Brukinsa)	
1.6 Rituximab	
1.7 Obinutuzumab (Gazyvaro)	

Q2. How many patients with **Chronic Lymphocytic Leukaemia** OR **Small B-Cell Lymphoma** – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available?

Name of medicine	Number patients treated
2.1 Acalabrutinib (Calquence)	
2.2 Ibrutinib (Imbruvica)	
2.3 Pirtobrutinib (Jaypirca)	
2.4 Venetoclax (Venclyxto)	
2.5 Zanubrutinib (Brukinsa)	
2.6 Obinutuzumab (Gazyvaro)	

2 September 2025

Name of medicine	Number patients treated
2.7 Rituximab	
2.8 Bendamustine	
2.9 Chlorambucil	
2.10 Fludarabine	
2.11 Cyclophosphamide	

Q3. How many patients with **Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma** were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?

Name of monotherapy or combination	Number patients treated
3.1 Ibrutinib + venetoclax	
3.2 Obinutuzumab + venetoclax	
3.3 Zanubrutinib monotherapy / maintenance	
3.4 Ibrutinib monotherapy / maintenance	
3.5 Venetoclax monotherapy	
3.6 Venetoclax + rituximab	

Q4. How many patients with **Mantle Cell Lymphoma** (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?

Name of monotherapy or combination	Number patients treated
4.1 Acalabrutinib	
4.2 Ibrutinib	
4.3 Zanubrutinib	

2 September 2025

Q5. How many patients with **Acute Myeloid Leukaemia** – ICD10 code = C920 - were treated with the following medicines in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?

Name of medicine	Number patients treated
5.1 Azacitidine	
5.2 Cytarabine	
5.3 Venetoclax (Venclyxto)	

Q6. How many patients with **Acute Myeloid Leukaemia** were treated with the following medicines in combination, in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?

Name of combination	Number patients treated
6.1 Venetoclax + Azacitidine (<i>with or without posaconazole</i>)	
6.2 Venetoclax + Cytarabine (<i>inc. V + LDAC, V + ARAC, V+ ARA-C</i>)	

Q7. How many patients with **Multiple Myeloma** were treated with the following medicines in combination, in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?

Name of medicine	Number patients treated
7.1 Daratumumab + Bortezomib + Dexamethasone [DVd]	
7.2 Daratumumab + Bortezomib + Thalidomide + Dexamethasone [DVTd]	
7.3 Daratumumab + Lenalidomide + Dexamethasone [DRD]	
7.4 Lenalidomide + Dexamethasone [Rd]	
7.5 Lenalidomide (monotherapy)	
7.6 Carfilzomib + Lenalidomide + Dexamethasone [KRd]	
7.7 Elotuzumab + Lenalidomide + Dexamethasone [ERd]	
7.8 Ixazomib + Lenalidomide + Dexamethasone [IRd]	

2 September 2025

Name of medicine	Number patients treated
7.9 Belantamab Mafodotin (monotherapy)	
7.10 Belantamab Mafodotin + Bortezomib + Dexamethasone [BVd]	
7.11 Any other combination containing Lenalidomide (please specify):	

BELFAST HEALTH AND SOCIAL CARE RESPONSE:

To provide the information requested above would involve a manual trawl of individual patient records. This would require in excess of 18 hours work to complete. This is because the Haematology Service does not have an electronic prescribing system for Systemic Anti-Cancer Treatments and the information is therefore not held centrally.

Belfast Trust considers that the cost of retrieving the information would be above the 'Appropriate Limit', as defined by the Freedom of Information Act under Section 12.

Section 12 of the Freedom of Information Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit. The limit has been specified as £450 for public authorities such as Belfast Trust. This represents the cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.